New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

Updated April 30th, 2023

New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

The FDA has approved PARP Inhibitor Olaparib for the treatment of advanced prostate cancer patients. Experts say this approval marks new personalized therapy options for specific tumors.

NOW
PLAYING
PSMA PET-CT Scans for Prostate Cancer: Accurately Staging and Treating High-Risk and Recurrent Disease
NOW
PLAYING
When Should I Get a Mammogram?
NOW
PLAYING
Actor Jeff Bridges Says This Is the Life-Changing Thing He Learned From Near-Death Battle With Cancer and COVID
NOW
PLAYING
Treatment Options When Mantle Cell Lymphoma Recurs
NOW
PLAYING
Imbruvica Treats Relapsed Lymphoma in a Different Way
NOW
PLAYING
New Immunotherapy-Chemo Combo Approved for Metastatic Bladder Cancer Patients Ineligible for Cisplatin-Based Treatment

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... prostate cancer trials in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

Later Stage Treatment: New Treatment Developments

SEE MORE   

  • Customizable treatment combinations are available for those facing advanced-stage prostate cancer.
  • Androgen deprivation therapy (ADT) lowers hormone levels that can fuel cancer.
  • Newer ADTs include: Xtandi (enzalutamide) and Erleada (apalutamide).
  • ADT can be combined with chemo, PARP inhibitors, or other drugs.
  • Approved PARP inhibitors are: Lynparza (olaparib) and Rubraca (rucaparib).

Later Stage Treatment: New Treatment Developments

  • Customizable treatment combinations are available for those facing advanced-stage prostate cancer.
  • Androgen deprivation therapy (ADT) lowers hormone levels that can fuel cancer.
  • Newer ADTs include: Xtandi (enzalutamide) and Erleada (apalutamide).
  • ADT can be combined with chemo, PARP inhibitors, or other drugs.
  • Approved PARP inhibitors are: Lynparza (olaparib) and Rubraca (rucaparib).
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.